BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, September 23, 2023
Home » Blogs » BioWorld Perspectives » What do Macroeconomics, Creativity and Upfront Payments Have in Common?

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld

What do Macroeconomics, Creativity and Upfront Payments Have in Common?

Aug. 24, 2011
By Trista Morrison
No Comments

What do macroeconomics, creativity and upfront payments have in common? They’re all featured in this week’s issue of BioWorld Insight!

I’m going to put on my long-discarded marketing hat for a minute and say I think we put together a really interesting issue of Insight this week. Of course as the Insight editor, I always think we’ve put together a really interesting issue . . . but just check this out:

  • Our cover story (Macro Woes Could Impact Biotech Financing, M&A) looks at how the S&P downgrade, increased unemployment, decreased consumer spending and other macroeconomic issues could trickle down to biotech. Analysts see haunting similarities between the economy today and at the beginning of the 2008 recession, which could mean challenges for biotech equity and convertible debt financings, lower valuations, more attrition risk, and more opportunistic M&A.
  • Another article (Upfront-Milestone Balance Shifting in Biotechs Favor) highlights Deloitte data showing that upfront payments in biotech licensing deals – which have been shrinking since 2000 – increased in the first half of 2011. On the M&A front, however, CVRs and earn-outs are on the rise.
  • Our third article (New Use for Cash? Amgen Gives NPS Royalty Advance) looks at how economic pressures are stimulating some out-of-the-box biotech solutions, such as Array BioPharma Inc. and Genentech’s clever product-agnostic ChK-1 inhibitor licensing deal, and NPS Pharmaceuticals Inc.’s decision to monetize a royalty stream with partner Amgen Inc. rather than with a traditional private equity group.
  • Plus there’s weekly Insight features including a fundraising chart, breaking news summary, deal-making data and more!
We reprinted this week’s Insight cover story on the economy in Monday’s issue of BioWorld Today, which I’m guessing most readers of this blog subscribe to. But if you missed it, or if you’d like to check out the whole issue of Insight, send me an email at trista.morrison@bioworld.com and I’ll email you a free copy.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • New NLRP3 inflammasome inhibitors named in PTC Therapeutics patent

    BioWorld Science
    PTC Therapeutics Inc. has patented new NLRP3 inflammasome inhibitors reported to be useful...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing